<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376166</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-0472</org_study_id>
    <nct_id>NCT02376166</nct_id>
  </id_info>
  <brief_title>Metformin for Rising PSA Remote Trial</brief_title>
  <acronym>M-RePoRT</acronym>
  <official_title>M-RePoRT: Metformin - Rising PSA Remote Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Galsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trials are critical to informing the care of patients with cancer. However, only
      3-5% of patients with cancer enroll in clinical trials. Poor accrual to trials has major
      implications with regards to the pace of progress, the cost of clinical cancer research, and
      the generalizability of results. The investigators have recently shown in an analysis of
      7,776 cancer clinical trials registered on clinicaltrials.gov that approximately 20% of
      cancer clinical trials fail to complete enrollment at all; the most often cited reason was
      poor accrual.

      Prior research has identified barriers to cancer clinical trial accrual that can be generally
      categorized in the domains of availability, awareness, and acceptance. Much attention has
      been paid to the barriers involvement awareness and acceptance - however, trial availability
      is likely a &quot;rate limiting step&quot;. This pilot study is the first in a series of planned steps
      to attempt to shift the current paradigm of &quot;bringing patients to trials&quot; to &quot;bringing trials
      to patients.&quot; With the integration of telemedicine visits, the investigators aim to decrease
      the burden of participation for patients, begin to address geographic barriers, and
      ultimately improve trial accrual. In this study, men with biochemically recurrent prostate
      cancer (a rising PSA after definitive local therapy) will receive the antidiabetic drug,
      metformin. Patients will require a single on-site visit for study enrollment. The remainder
      of the 6 month study will be conducted via a HIPPA secure telemonitoring system (monthly
      visits conducted via telemedicine with tablet computers provided to each patients).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men with an isolated PSA recurrence after local therapy are an ideal population for the
      evaluation of novel therapies given the minimal disease burden, generally indolent natural
      history, and patients' preference to avoid the adverse effects of androgen deprivation
      therapy. Metformin has shown anti-prostate cancer activity in preclinical models and cohort
      studies. Metformin, a biguanide oral antihyperglycemic agent, abrogates hyperinsulinemia in
      individuals with and without diabetes and has shown promising anti-prostate cancer activity
      in preclinical models, epidemiologic studies, and retrospective cohorts. Several
      epidemiologic/retrospective studies have shown that metformin has a positive impact on
      overall survival among men with prostate cancer.

      These nonclinical and clinical studies have led to calls for prospective studies of metformin
      in patients with prostate cancer. This is a pilot telemedicine study of metformin in patients
      with a rising PSA (&quot;biochemical recurrence&quot;) after definitive local therapy for prostate
      cancer.

      The current study is supported by the following rationale:

        -  A large proportion of clinical trials close prematurely due to poor accrual.

        -  Geographic inaccessibility is a barrier to clinical trial participation.

        -  Metformin is a safe and inexpensive medication that has demonstrated anti-prostate
           cancer activity in nonclinical and epidemiologic studies. Importantly, metformin has
           been shown to be safe in non-diabetic patients (e.g., patients with polycystic ovary
           disease) and does not cause hypoglycemia.

        -  Use of novel technologies may facilitate clinical trial accrual and minimize the burden
           of participation for patients. Ultimately, these approaches may also decrease the cost
           of drug development and increase the pace of progress.

      In the absence of prohibitive toxicities or disease progression (defined in 4.4), patients
      may continue treatment for the 6-month study period. This study will include a baseline visit
      for study enrollment at Mount Sinai. The remainder of the visits will be telemedicine visits
      conducted using secure video conferencing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Completed All Telemedicine Visits</measure>
    <time_frame>6 months</time_frame>
    <description>Feasibility will be defined as completion of all telemedicine visits by &gt; 2/3 of enrolled patients (unless treatment discontinued early for toxicity or disease progression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Stable PSA Levels at 6 Months as Defined by a &lt;20% Change</measure>
    <time_frame>baseline and 6 month</time_frame>
    <description>Percent of patients with 6-month PSA stable 20% change at 6 months as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence With Metformin as Measured by Electronic Pill Adherence Monitoring</measure>
    <time_frame>6 months</time_frame>
    <description>Adherence with metformin as measured by electronic pill adherence monitoring. Patients were provided with an electronic medication dispenser/medication adherence monitoring device. The device provided audible and visual reminders to proceed with drug dosing and was equipped with a cellular modem that registers a signal to a cloud-based database each time a patient accessed his or her study medication. However, the size and shape of the metformin pills caused the device to malfunction frequently, which led patients to access the pills from the device manually; the data, therefore, could not be used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 1</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial in the future&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 2</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a telemedicine clinical trial in the future&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 3</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;The time commitment required for participation in this trial was not overly burdensome&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 4</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;Participation in this trial did not disrupt my work or other activities&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 5</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I found it easy to use the telemonitoring tablet computer&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 6</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the travel burden for participation in clinical trials for patients&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 7</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the financial burden of participation in clinical trials for patients&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 8</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;My local physician was adequately informed about my participation in this trial (if applicable)&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 9</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt I was monitored sufficiently closely while enrolled in this trial&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 10</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would recommend participation in a telemedicine clinical trial to other patients&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 11</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial where the entire trial was conducted remotely without requiring any visits to the study center&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 12</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt that I was able to communicate well with the study team, even though most contact was through the tablet computer video instead of in person&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency to Have a Bowel Movement Episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of urgency to have a bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased Frequency of Bowel Movements</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of Increased frequency of bowel movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Watery Bowel Movements</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 2st reported outcome - Number of episodes of watery bowel movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Flatulence</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 3rd reported outcome - Number of episodes of flatulence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Bloating</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 4th reported outcome - Number of episodes of bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Nausea</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 5th reported outcome - Number of episodes of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Vomiting</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 6th reported outcome - Number of episodes of vomiting</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>850 mg PO once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate. (*in situations where
             pathology reports documenting prostate cancer are no longer available such as when the
             initial biopsy or prostatectomy was performed in the remote past, a documented history
             of prior prostate cancer and prostate cancer treatment in prior medical records will
             be sufficient)

          -  Biochemical disease progression after radical prostatectomy and/or radiation therapy
             (external-beam radiation therapy and/or brachytherapy), and no radiographic evidence
             of metastases.

               -  Men with history of radical prostatectomy are required to have baseline PSA &gt; 0.5
                  ng/mL (Prior treatment with neoadjuvant, adjuvant, or salvage radiation therapy
                  is allowed, again, with screening PSA greater than or equal to 0.5 ng/mL required
                  for eligibility).

               -  Men treated with primary radiation therapy are required to have baseline PSA ≥
                  1.0 ng/mL above their post radiation nadir for men who were treated with primary
                  radiation therapy (external beam and/or brachytherapy). Men who had primary
                  radiation therapy followed by salvage prostatectomy are eligible if screening PSA
                  is greater than or equal to 0.5 ng/mL.

               -  Men with previous neoadjuvant adjuvant hormone therapy are eligible if
                  testosterone level at screening is non-castrate (≥ 50 ng/dl). Men previously
                  treated with intermittent hormonal therapy are also eligible if level of
                  testosterone at screening is non-castrate (≥ 50 ng/dl).

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
             (Karnofsky greater than or equal to 60%).

          -  Subjects must have normal organ as defined below:

               -  AST(SGOT)/ALT(SGPT) less than or equal to 1.8 X institutional upper limit of
                  normal

               -  Serum bilirubin ≤ ULN (except for subjects with Gilbert's Disease who are
                  eligible despite elevated serum bilirubin level)

               -  Creatinine ≤ 1.5 mg/dL and/or creatinine clearance &gt; 60 ml/min

          -  English speaking

        Exclusion Criteria:

          -  Concurrent use of other investigational agents or other prostate cancer therapies
             (e.g., androgen deprivation therapy)

          -  Currently taking metformin, sulfonylureas, thiazolidinedione, insulin, or other
             antidiabetic drugs for any reason.

          -  Known hypersensitivity or intolerance to metformin

          -  Condition associated with increased risk of metformin-associated lactic acidosis:

               -  New York Heart Association Class III or IV Heart Failure

               -  Intake of 3 or more alcoholic beverages per day

               -  Known history of lactic acidosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Galsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, and Oh W. JCO Clinical Cancer Informatics 2017 :1, 1-10</citation>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>October 18, 2017</results_first_submitted>
  <results_first_submitted_qc>November 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2017</results_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Matthew Galsky</investigator_full_name>
    <investigator_title>Associate Professor, Medicine, Hematology and Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>850 mg PO once daily for 4 weeks
Metformin: 850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued metformin early</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>850 mg PO once daily for 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="57" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Radical prostatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years from local therapy to study enrollment</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" lower_limit="1.2" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline PSA</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" lower_limit="0.52" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>One-way driving distance to study center</title>
          <units>miles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" lower_limit="2.4" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>One-way driving time to study center</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="12" upper_limit="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Completed All Telemedicine Visits</title>
        <description>Feasibility will be defined as completion of all telemedicine visits by &gt; 2/3 of enrolled patients (unless treatment discontinued early for toxicity or disease progression).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Completed All Telemedicine Visits</title>
          <description>Feasibility will be defined as completion of all telemedicine visits by &gt; 2/3 of enrolled patients (unless treatment discontinued early for toxicity or disease progression).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Stable PSA Levels at 6 Months as Defined by a &lt;20% Change</title>
        <description>Percent of patients with 6-month PSA stable 20% change at 6 months as compared to baseline</description>
        <time_frame>baseline and 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stable PSA Levels at 6 Months as Defined by a &lt;20% Change</title>
          <description>Percent of patients with 6-month PSA stable 20% change at 6 months as compared to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence With Metformin as Measured by Electronic Pill Adherence Monitoring</title>
        <description>Adherence with metformin as measured by electronic pill adherence monitoring. Patients were provided with an electronic medication dispenser/medication adherence monitoring device. The device provided audible and visual reminders to proceed with drug dosing and was equipped with a cellular modem that registers a signal to a cloud-based database each time a patient accessed his or her study medication. However, the size and shape of the metformin pills caused the device to malfunction frequently, which led patients to access the pills from the device manually; the data, therefore, could not be used for analysis.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence With Metformin as Measured by Electronic Pill Adherence Monitoring</title>
          <description>Adherence with metformin as measured by electronic pill adherence monitoring. Patients were provided with an electronic medication dispenser/medication adherence monitoring device. The device provided audible and visual reminders to proceed with drug dosing and was equipped with a cellular modem that registers a signal to a cloud-based database each time a patient accessed his or her study medication. However, the size and shape of the metformin pills caused the device to malfunction frequently, which led patients to access the pills from the device manually; the data, therefore, could not be used for analysis.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 1</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial in the future&quot;.</description>
        <time_frame>6 months</time_frame>
        <population>2 patients did not complete the questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 1</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial in the future&quot;.</description>
          <population>2 patients did not complete the questionnaire</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 2</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a telemedicine clinical trial in the future&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 2</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a telemedicine clinical trial in the future&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 3</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;The time commitment required for participation in this trial was not overly burdensome&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 3</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;The time commitment required for participation in this trial was not overly burdensome&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 4</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;Participation in this trial did not disrupt my work or other activities&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 4</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;Participation in this trial did not disrupt my work or other activities&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 5</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I found it easy to use the telemonitoring tablet computer&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 5</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I found it easy to use the telemonitoring tablet computer&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 6</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the travel burden for participation in clinical trials for patients&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 6</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the travel burden for participation in clinical trials for patients&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 7</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the financial burden of participation in clinical trials for patients&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 7</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;This telemedicine approach eases the financial burden of participation in clinical trials for patients&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 8</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;My local physician was adequately informed about my participation in this trial (if applicable)&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 8</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;My local physician was adequately informed about my participation in this trial (if applicable)&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 9</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt I was monitored sufficiently closely while enrolled in this trial&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 9</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt I was monitored sufficiently closely while enrolled in this trial&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 10</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would recommend participation in a telemedicine clinical trial to other patients&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 10</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would recommend participation in a telemedicine clinical trial to other patients&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 11</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial where the entire trial was conducted remotely without requiring any visits to the study center&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 11</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I would participate in a clinical trial where the entire trial was conducted remotely without requiring any visits to the study center&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 12</title>
        <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt that I was able to communicate well with the study team, even though most contact was through the tablet computer video instead of in person&quot;.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction as Measured by a Patient Satisfaction Survey Question 12</title>
          <description>Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - &quot;I felt that I was able to communicate well with the study team, even though most contact was through the tablet computer video instead of in person&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither agree nor disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urgency to Have a Bowel Movement Episodes</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of urgency to have a bowel movement</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Urgency to Have a Bowel Movement Episodes</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of urgency to have a bowel movement</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increased Frequency of Bowel Movements</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of Increased frequency of bowel movements</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Increased Frequency of Bowel Movements</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of Increased frequency of bowel movements</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Watery Bowel Movements</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 2st reported outcome - Number of episodes of watery bowel movements</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Watery Bowel Movements</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 2st reported outcome - Number of episodes of watery bowel movements</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Flatulence</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 3rd reported outcome - Number of episodes of flatulence</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Flatulence</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 3rd reported outcome - Number of episodes of flatulence</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Bloating</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 4th reported outcome - Number of episodes of bloating</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Bloating</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 4th reported outcome - Number of episodes of bloating</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Nausea</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 5th reported outcome - Number of episodes of nausea</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Nausea</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 5th reported outcome - Number of episodes of nausea</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Vomiting</title>
        <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 6th reported outcome - Number of episodes of vomiting</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Vomiting</title>
          <description>Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 6th reported outcome - Number of episodes of vomiting</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Big problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>850 mg PO once daily for 4 weeks Metformin: 850 mg PO twice daily for 5 months (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade &gt; 1 toxicities)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Dehydration from anorexia and nausea requiring hospitalization. Resolved with discontinuation of metformin and intravenous hydration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Consitipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Queasiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation was the need for a single onsite enrollment visit, which likely still represents a significant geographic barrier to trial accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Matthew D. Galsky</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 659-5599</phone>
      <email>matthew.galsky@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

